Similar to the HER-1 immunosensor, also for HER-2, the linear detection range of the normal assay (5–200 ng mL−1) and serum assay (5–80 ng mL−1) as well as their LODs fall within the clinical detection range of HER-2 in breast cancer and healthy patients. This evidence concerns the gene EGFR and breast carcinoma.